Hanmi Science’s M&A on ‘JVM’ through investing KRW 129 billion

On the 9^th, the holding company of Hanmi Pharm, Hanmi Science(CEO Jong-yoon Lim) officially announced the M&A of JVM, a global company in the automated medication management system field, through the stock swapping method.

Hanmi Science secured JVM’s 1,899,272 shares(30%) by investing the total KRW 129 billion(20% cash, 80% treasury stocks). Particularly, since it is the first cases in the pha...